Pre-market 11 Feb 2026 ISRG stock $492.84 NASDAQ: AI surgical upside 22.62%

ISRG stock opened pre-market at $492.84 on NASDAQ on 11 Feb 2026, signaling a cautious market ahead of AI-led product catalysts. The price sits well below the 52-week high of $609.08 and above the 52-week low of $425.00, while volume is running at 2,208,124 shares. We assess recent earnings, valuation, technical signals, and AI opportunities that could re-rate Intuitive Surgical, Inc. (NASDAQ: ISRG) in the United States market.

ISRG stock: pre-market price and key metrics

Pre-market ISRG stock is priced at $492.84 with a market cap of USD 175.84 billion and EPS 7.86. The trailing P/E is 63.00 and the 50-day average price is $548.83. Daily range shows $483.90 to $493.54, with average volume 1,888,404. These metrics frame a premium valuation for a healthcare technology leader.

ISRG analysis: earnings, revenue and growth drivers

Intuitive Surgical reported $2.53 EPS and USD 2.87 billion revenue for the quarter ending January 22, 2026. Revenue rose 18.8% year over year, driven by system placements and higher instrument attach rates. Growth drivers include the da Vinci surgical platform, Ion endoluminal system, and expanding digital services that lean on AI-enabled workflow insights.

ISRG forecast and price targets

Wall Street consensus target averages USD 617.23, based on recent brokerage notes. Meyka AI’s forecast model projects a 12-month target of USD 604.32, implying 22.62% upside from USD 492.84. Forecasts are model projections and not guarantees. Analysts still show a Moderate Buy consensus with mixed near-term valuation views.

ISRG technicals and trading signals for pre-market

Technicals show momentum but some near-term caution: RSI 65.69, MACD histogram 0.11, and ADX 22.53. The stock trades below its 50-day average at $548.83 but near the 200-day average $516.45. ATR is 11.47, indicating moderate volatility for pre-market trading.

ISRG analysis of risks and AI sector opportunities

Intuitive faces valuation risk with price-to-sales 17.52 and price-to-book 10.41. Insider selling totaled 70,011 shares in recent months, a cautionary signal. Opportunities include AI-enabled surgical automation, instrument recurring revenue, and diagnostics expansion through Ion. Competitive and reimbursement risks remain material for investors.

Meyka rating and investment stance on ISRG stock

Meyka AI rates ISRG with a score out of 100: 78.58 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade is informational, not investment advice.

Final Thoughts

Key takeaway: ISRG stock trades at USD 492.84 pre-market on 11 Feb 2026, with recent earnings showing solid top-line growth and margins. Analysts’ average price target is USD 617.23, while Meyka AI’s forecast model projects USD 604.32, implying 22.62% upside versus current levels. The business shows strong cash generation, a current ratio near 4.73, and R&D spend above 13% of revenue, supporting product-led growth and AI integration. Investors should weigh that strength against a high P/E of 63.00, thin margin for error on execution, and recent insider sales. For AI-focused portfolios, ISRG offers exposure to robotic surgery and diagnostics. For broader portfolios, valuation and near-term volatility suggest selective position sizing and monitoring around upcoming catalysts and the April earnings announcement. For more data-driven context, see our Meyka AI-powered market analysis on ISRG at Meyka ISRG page. Sources: latest coverage at CNBC and MarketBeat reports on recent filings and analyst notes MarketBeat.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.